Antibody Drug Conjugates Market Size and Forecasts (2020 – 2030)

Antibody Drug Conjugates Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology (Cleavable Linker and Non-Cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Send Enquiry
Item ID: TIPRE00003494 Category: Tags: , ,

$3,185$5,985

Description

The global antibody drug conjugates market is expected to reach US$ 7.793 billion in 2022 to US$ 29.600 billion by 2030; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.

The market growth of antibody drug conjugates is attributed to growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. However, high cost of ADCs development and commercialization is hindering the market growth.

Growing Strategic Partnerships to Develop Antibody Drug Conjugates

Antibody–drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc.’s first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For intance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.

Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates. Whereas for Mainland China, Hing Kong, and Macau, Kelun-Biotech has retained its rights to research, develop, manufacture, and commercialize certain licensed and option ADCs.

Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBio’s lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells’ aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.

Antibody Drug Conjugates Market: Segmental Overview

The antibody drug conjugates market is segmented on the basis of technology, application, distribution channel, and geography. Based on technology, the antibody drug conjugates market is bifurcated into cleavable linkers and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Cleavable linkers use a chemical trigger or inherent properties of their structure to release the cytotoxic payload in the tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates (ADCs). According to the article “Antibody–drug conjugates: Recent advances in linker chemistry,” published in March 2021, over 80% of the approved ADCs are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of ADCs synthesized using this technology. These ADCs remain comparatively stable for a long time in blood circulation after releasing hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly.

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR of 18.6% during 2022–2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

Antibody Drug Conjugates Market: Geographical Overview

North America holds the largest share of the antibody drug conjugates market. The antibody drug conjugates market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest numbers of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA’s data published in May 2021, 113 clinical trials were in studies for 77 novel ADCs that targeted over 40 different targets. The growing list of ADCs in the pipeline is estimated to enhance the antibody drug conjugate market size in the country in the coming future.

In addition, growing partnerships among antibody drug conjugate market leader will expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogen’s ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

A few of the major primary and secondary sources referred to while preparing the ADC market report on the US Food and Drug Administration (FDA), Cancer.Net, EMA (European Medicines Agency), and Centers for Disease Control and Prevention (CDC).

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Breast Cancer Segment by Application to Account Larger Share in Antibody Drug Conjugates Market during 2022–2030

According to our new research study on “Antibody Drug Conjugates Market Forecast to 2030 –Global Analysis – by Technology, Application, and Distribution Channel,” the market was valued at US$ 7.793 billion in 2022; and is expected to reach US$ 29.600 billion by 2030 and it estimated to grow at a rate of 18.2% from 2022 to 2030. The report highlights trends prevailing in the market, and factors driving and hindering the antibody drug conjugates market growth.

The market growth of antibody drug conjugates is due to the growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas high cost of ADCs development and commercialization is hindering the market growth.

The antibody drug conjugates market, by application, is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR during 2022–2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve breast cancer therapeutics’ potency, precision, and safety. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

Asia Pacific is the fastest-growing region of the global newborn screening market in 2022. The projected growth of the market in this region can be associated with the growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials. China is home to various innovators of ADCs that are exponentially contributing to the market growth. Players such as RemeGen Co., Ltd.; Zhejiang Medicine Co., Ltd.; and Jiangsu Hengrui Pharmaceuticals Company Ltd. are among the leaders in the ADCs market in the country. These companies are involved in developing ADCs that can treat breast, gastric, and urothelial cancers.

Companies have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.

As of April 2023, Zhejiang Medicine Co., Ltd. and Jiangsu Hengrui Pharmaceuticals Company Ltd. have ARX788 + pyrotinib maleate and SHR-A1811 + pyrotinib maleate, respectively, in phase II and are developed to treat breast cancer. Thus, the commercialization of pipeline products in the country would help the market grow exponentially in the coming years.

ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, ImmunoGen, Inc., GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are among the leading companies operating in the vital signs monitoring devices market.

Companies operating in the antibody drug conjugates market adopt various organic and inorganic strategies. Growth strategies mainly include product launches and product approvals, mergers & acquisitions, collaborations, and partnerships are among the growth strategies witnessed in the antibody drug conjugates market.

A few of the significant developments by key market players are listed below.

• In September 2022, Seagen Inc., pioneer and a world leader in antibody drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagen’s world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin.

• In September 2022, ImmunoGen, Inc. has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. The collaboration further supports the strategy to bring ELAHERE to eligible patients with folate receptor Alpha (FR?)-Positive, platinum-resistant ovarian cancer globally.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Wire Harness Market Landscape
4.1 Market Overview
4.2 North America PEST Analysis
4.3 Ecosystem Analysis
4.4 Expert Opinions
5. North America Wire Harness Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Technological Advancements in Automobiles
5.1.2 Increasing Wire and Cable Consumption
5.2 Market Restraints
5.2.1 Rising Counterfeit Products That Can Cause Catastrophe
5.3 Market Opportunities
5.3.1 Technological Advancements in Food & Beverages and Agriculture
5.4 Future Trends
5.4.1 Increasing Usage of Lightweight Wire Harness
5.5 Impact Analysis of Drivers and Restraints
6. Wire Harness Market – North America Market Analysis
6.1 North America Wire Harness Market Overview
6.2 North America Wire Harness Market Revenue Forecast and Analysis
7. North America Wire Harness Market Analysis – By Component
7.1 Overview
7.2 North America Wire Harness Market, By Component (2022 and 2030)
7.3 Wire Harness Connector
7.3.1 Overview
7.3.2 Wire Harness Connector: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Wire Harness Terminal
7.4.1 Overview
7.4.2 Wire Harness Terminal: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Wire Harness Market Analysis – By Material
8.1 Overview
8.2 North America Wire Harness Market, By Material (2022 and 2030)
8.3 PVC
8.3.1 Overview
8.3.2 PVC: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Vinyl
8.4.1 Overview
8.4.2 Vinyl: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Thermoplastic Elastomer
8.5.1 Overview
8.5.2 Thermoplastic Elastomer: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Polyurethane
8.6.1 Overview
8.6.2 Polyurethane: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Polyethylene
8.7.1 Overview
8.7.2 Polyethylene: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Wire Harness Market Analysis – By End User
9.1 Overview
9.2 North America Wire Harness Market, By End User (2022 and 2030)
9.3 Automotive
9.3.1 Overview
9.3.2 Automotive: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.1 Two-Wheelers
9.3.2.2 Two-Wheelers: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.3 Construction Vehicles
9.3.2.4 Construction Vehicles: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.5 Passenger Cars
9.3.2.6 Passenger Cars: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.7 Commercial Vehicles
9.3.2.8 Commercial Vehicles: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Marine
9.4.1 Overview
9.4.2 Marine: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Aerospace & Defense
9.5.1 Overview
9.5.2 Aerospace & Defense: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Consumer Durables
9.6.1 Overview
9.6.2 Consumer Durables: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.7 Medical
9.7.1 Overview
9.7.2 Medical: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.8 Agriculture
9.8.1 Overview
9.8.2 Agriculture: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.9 Industrial
9.9.1 Overview
9.9.2 Industrial: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
9.10 Others
9.10.1 Overview
9.10.2 Others: North America Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Wire Harness Market – Country Analysis
10.1 Overview
10.1.1 North America Wire Harness Market- by Key Country
10.1.1.1 US: Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 US: Wire Harness Market- by Component
10.1.1.1.2 US: Wire Harness Market- By Material
10.1.1.1.3 US: Wire Harness Market- By End User
10.1.1.1.4 US: Wire Harness Market- By Automotive
10.1.1.2 Canada: Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Canada: Wire Harness Market- by Component
10.1.1.2.2 Canada: Wire Harness Market- By Material
10.1.1.2.3 Canada: Wire Harness Market- By End User
10.1.1.2.4 Canada: Wire Harness Market- By Automotive
10.1.1.3 Mexico: Wire Harness Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Mexico: Wire Harness Market- by Component
10.1.1.3.2 Mexico: Wire Harness Market- By Material
10.1.1.3.3 Mexico: Wire Harness Market- By End User
10.1.1.3.4 Mexico: Wire Harness Market- By Automotive
11. Industry Landscape
11.1 Market Initiative
11.2 Merger and Acquisition
11.3 New Development
12. Company Profile
12.1 DRÄXLMAIER Group
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Fujikura Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Lear Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sumitomo Electric Industries, Ltd.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 LEONI AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Yazaki Corporation
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 FURUKAWA ELECTRIC CO., LTD.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Motherson Sumi Systems Ltd.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 YURA Corporation
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About
13.2 Word Index

LIST OF TABLES

Table 1. Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. New Cancer Cases Worldwide, in 2020
Table 4. List of FDA-Approved ADCs
Table 5. North America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 6. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 7. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 8. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 9. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 10. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 11. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 12. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 13. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 14. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 15. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 16. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 17. Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 18. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 19. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 20. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 21. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 22. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 23. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 24. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 25. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 26. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 27. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 28. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 29. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 30. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 31. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 32. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 34. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 35. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 36. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 37. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 38. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 39. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 40. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 41. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 42. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 43. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 44. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 45. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 46. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 47. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 48. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 49. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 50. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 51. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 52. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 53. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 54. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 55. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 56. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 57. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 58. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 59. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 60. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 61. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 62. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 63. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 64. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 65. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 66. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 67. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 68. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 69. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 70. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 71. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 72. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 73. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 74. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 75. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 76. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 77. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 78. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 79. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 80. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 81. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 82. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 83. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 84. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 85. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 86. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 87. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 88. Glossary of Terms, Antibody Drug Conjugates Market

LIST OF FIGURES

Figure 1. Antibody Drug Conjugates Market Segmentation, By Region
Figure 2. Key Insights
Figure 3. Global – PEST Analysis
Figure 4. Antibody Drug Conjugates Market – Key Industry Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 7. Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 8. Cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Non-Cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 11. Blood Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Breast Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Ovarian Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Urothelial Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 17. Hospital Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Retail Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Online Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 21. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 23. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 27. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Europe: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 29. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 36. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 38. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 45. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 47. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 52. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 54. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

The List of Companies – Antibody Drug Conjugates Market
– ADC Therapeutics SA
– Pfizer Inc.
– F. Hoffmann-La Roche Ltd
– ImmunoGen, Inc.
– GSK Plc
– Gilead Sciences Inc.
– AstraZeneca Plc
– Astellas Pharma Inc.
– RemeGen Co Ltd
– Takeda Pharmaceutical Co Ltd

Reviews

There are no reviews yet.

Be the first to review “Antibody Drug Conjugates Market Size and Forecasts (2020 – 2030)”